urothelial cancer – Talk Bio

Actionable Insights Powered by AI

Corbus’ Nectin-4 ADC Shows Promise in Western Study, Challenging Pfizer’s Padcev

2 months ago talkbio0Tagged Antibody-Drug Conjugates, ASCO-GU, Cancer of Neck, Clinical Trials, Corbus Pharmaceuticals, CRB-701, NECTIN4 gene, Padcev, urothelial cancer

Corbus Pharmaceuticals, CRB-701, antibody-drug conjugate, Nectin-4, urothelial cancer, head and neck cancer, Padcev, clinical trial, ASCO-GU 2025

Gilead Withdraws US Indication for Sacituzumab Govitecan in Metastatic Urothelial Cancer

6 months ago talkbio0Tagged Accelerated, Approved, Govitecan, Malignant neoplasm of urinary bladder, sacituzumab, Trodelvy, United States Food and Drug Administration, urothelial cancer, Withdraw (activity)

Sacituzumab Govitecan, Trodelvy, Bladder Cancer, Urothelial Cancer, Gilead Sciences, FDA, Accelerated Approval Withdrawal

Gilead’s Trodelvy Fails to Meet Primary Endpoint in Confirmatory Trial for Urothelial Cancer

11 months ago talkbio0Tagged Antibody-Drug Conjugates, Approved, Clinical Trials, Gilead Sciences, Neoplasms, Overall Survival, Trodelvy, TROPiCS-04 study, United States Food and Drug Administration, urothelial cancer

Gilead Sciences, Trodelvy, urothelial cancer, TROPiCS-04 study, overall survival, antibody-drug conjugate, oncology, clinical trials, FDA approval